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ABSTRACT 
  
  
 
  
QUANTIFYING POLYPHARMACY IN DIABETES PATIENTS IN THE U.S. 
 
 
By  Jing Tao, BPharm, M. S. 
  
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
  
Virginia Commonwealth University, 2011. 
  
Major Director: David A. Holdford, Ph.D. 
Associate Professor, Department of Pharmacy 
 
Objectives: To quantify polypharmacy and assess the socio-economic predictors of medication 
use and expenditure in diabetics. 
x 
 
Methods: This study analyzed adult diabetes patients using a nationally representative sample in 
Medical Expenditure Panel Survey in 2006.  Top ten most highly utilized drug classes were 
identified. Descriptive statistics were used to portray the patients’ medication utilization and 
spending. Generalized linear models were conducted to assess the socio-economic variants in 
drug use and spending.  
Results:  On average, a diabetes patient had 45 prescriptions in 2006, for total annual spending 
of $3,161. A diabetes patient used drugs from 3.43 classes within top ten drug classes. Races and 
insurance coverage are associated with drug use and spending, holding other factors constant. 
Conclusion: Diabetes patients use multiple classes of drugs. Insurance coverage and races are 
related with drug spending and utilization. More research is needed to evaluate the potential risks 
of drug-drug interactions due to polypharmacy. 
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CHAPTER 1 
Introduction 
 
1.1 Background 
Diabetes mellitus is a group of chronic diseases characterized by hyperglycemia.   According 
to the World Health Organization’s (WHO) definition, diabetes mellitus describes a metabolic 
disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin 
action, or both.  Generally, diabetes is categorized into four clinical classes: (1) Type 1 diabetes, 
(2) Type 2 diabetes, (3) Other specific types of diabetes, and (4) Gestational diabetes. Type 1 
diabetes was previously called insulin-dependent diabetes because it usually strikes children and 
young adults.  This form of diabetes results from destroyed pancreatic β-cell which is the only 
cells in the body that make the hormone insulin that regulates blood glucose.  To survive, 
patients with Type 1 diabetes must have insulin delivered by injection or a pump.  In adults, type 
1 diabetes accounts for 5% to 10% of all diagnosed cases of diabetes 
[1]
.  Type 2 diabetes results 
from a progressive insulin secretary defect on the background of insulin resistance. Type 2 
diabetes is by far the most common type of diabetes.  In adults, type 2 diabetes accounts for 
about 90%-95% of all diagnosed cases of diabetes 
[1]
.  This form of diabetes was previously 
called noninsulin-dependent diabetes.  It usually begins as insulin resistance, a disorder in which 
insulin is not used properly in the body.  As the need for insulin rises, the pancreas gradually 
loses its ability to produce it.  Type 2 diabetes is often associated with older age, obesity, family 
history of diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity.  Other 
specific types of diabetes result from other causes such as infections, diseases of the exocrine 
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pancreas, surgery, and drug- or chemical-induced diabetes.  This type of diabetes accounts for 
only 1% to 5% of all diagnosed cases 
[1]
.  Gestational diabetes mellitus (GDM) is a form of 
glucose intolerance that is newly diagnosed during pregnancy 
[2] [3]
.   This type of diabetes is 
more common among obese women and women with a family history of diabetes. During 
pregnancy, it requires treatment to normalize maternal blood glucose levels to avoid 
complications in the infant.  Despite the difference in pharmaceutical treatment for type 1 and 
type 2 diabetes, both share similar complications.  Diabetes is highly associated with 
cardiovascular complications such as coronary heart disease (CHD), large plaque burden and 
myocardial infarction (MI)
 [4]-[6]
. Other diabetic-related complications include nephropathy, 
neuropathy, and retinopathy 
[7]
. 
    Diabetes has reached epidemic proportions in the United States.  According to the most recent 
report from Center for Disease Control and Prevention (CDC), 25.8 million Americans have 
diabetes and an estimated 79 million adults have pre-diabetes 
[2]
. The disease and its 
complications is one of the most expensive medical conditions in the US and ranks seventh as a 
leading cause of death in the nation 
[2]
.  Economically, diabetes imposes an increasing economic 
burden on national health care systems. Research has reported that the total costs of diagnosed 
diabetes in the United States in 2007 were $174 billion 
[8]
.  After adjusting for demographic 
differences, average medical expenditures among people with diagnosed diabetes were 2.3 times 
higher than for nondiabetics 
[8]
.  The increasing diabetes prevalence, the complexity of its 
complications, and the high cost of the treatment, presents challenges to diabetes management 
and cost control.  
Pharmaceutical intervention plays an important role in preventing the progression of diabetes 
complications such as the cardiovascular disease 
[9]
.  Pharmaceuticals are used to provide tight 
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control of blood glucose levels, blood pressure, and cholesterol levels 
[10]
.  Intensive glycemic 
control with insulin therapy in type 2 diabetes patients can delay the onset and progression of 
diabetic retinopathy, nephropathy and neuropathy 
[11]
.  Similar benefits have been shown in 
therapies for individuals with type II diabetes 
[12]
.  The UK Prospective Diabetes Study indicated 
that intensive control of blood pressure and blood glucose reduce the risk of complications in 
type 2 diabetes patients 
[13][14]
.  A randomized placebo-controlled trial in UK reported that 
cholesterol lowering medication can significantly reduce the major coronary events, strokes and 
revascularisations 
[15]
.  The STENO-2 study indicated that diabetes patients significantly benefit 
from an intensified, targeted intervention including using ACE Inhibitors or ARBs, smoking 
cessation and dietary interventions 
[16]
.  The underlying pathology of cardiovascular diseases in 
diabetes patients is complicated and likely multi-factorial.  Consequently, several therapeutic 
medications should be considered into the comprehensive diabetes care beyond glucose control.  
Based on these results, clinical practice guidelines have recommended a more intensive form 
of diabetes care with multi-targets of medical care.  Multiple drug therapy is generally required 
in the treatment for complications for patients with diabetes. For glycemic control, the American 
Diabetes Association (ADA) recommends that A1C targets be below or around 7% for diabetes 
due to the strong association between A1C level and macrovascular complications
 [2]
.  For 
hypertension, the blood pressure target has been lowered from 130/85 mmHg to 130/80 mmHg 
based upon ADA recommendations 
[10]
. The ADA also recommended that patients with high 
blood pressure ≥140/90 mmHg should receive pharmacologic therapy including either an ACE 
inhibitor or an angiotensin II receptor blocker (ARB), supplemented with a thiazide diuretic if 
necessary 
[2]
.  For dyslipidemia in diabetes, statin therapy is recommended to achieve a LDL 
cholesterol level < 100mg/dl (2.60 mmol/l), regardless of baseline lipid levels 
[2]
.  Additionally, 
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anti-platelet agents may also be considered as a primary cardiovascular risk prevention strategy 
for elderly diabetic patients.  Recommended therapy includes aspirin (75-162 mg/day) for those 
who at increased cardiovascular risk or clopidogrel (75 mg/day) and aspirin for those who had an 
acute coronary syndrome history 
[2]
.   
Each of the guidelines and clinical recommendations indicates the likelihood that 
comprehensive treatments of diabetic patients will involve several medications across different 
therapeutic drug classes. Hence, polypharmacy, which is defined as the prescriptions of multiple 
medications simultaneously 
[20]
, has become a salient consideration in the care of patients with 
diabetes. The major consequences of polypharmacy for diabetes patients include adverse drug 
reactions (ADRs), drug-drug interactions, increased drug costs, decreased medication adherence, 
potential duplicated therapy, as well as additional demands for health care services and decreased 
quality of life 
[17]
.  It is noted that with the accelerating rate of drug cost increasing, the financial 
burden of larger drug regimens may become particularly important for the society.  It has been 
suggested that patients’ regimens should be regularly reviewed and evaluated in order to achieve 
optimum control of medical problems as well as to keep lower drug costs. 
 
1.2 Objectives and specific aims 
    The aim of this research was to study the patterns of medication prescription in a nationally 
representative cohort of adult diabetic patients in 2006.  The primary goal was to describe the 
number of prescriptions and drug classes used among diabetes patients on a personal level, and 
to quantify the spending on the diabetes-related medications.  The secondary goal was to assess 
socio-economic variants in this patient population.   
    The study has following specific aims: 
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Specific aim 1: To list top ten drug classes by utilization among diabetes patients. 
Specific aim 2: To describe the demographic characteristics (age, gender, and race) of the patient 
sample. 
Specific aim 3: To calculate the average total drug cost, average out-of-pocket payment, and 
average number of prescriptions, and average number drug classes.  
Specific aim 4: To evaluate the socio-economic predictors of  medication use and drug spending 
among the diabetes patients, controlling for age, gender, race, geographic regions, marital status, 
general health perception and co-morbid diseases.  
 
1.3 Significance 
    There is abundant evidence that tight control of glucose, blood pressure, and cholesterol levels 
decreases the risk of developing diabetes and its related macro- and microvascular complications 
and cardiovascular death 
[7] [13] [14] [18] [19]
.  On the other hand, the undesired consequences of 
multiple medications for diabetes have been described 
[20]-[23]
.  This includes adverse drug 
reactions, medication errors and increased risks of nonadherence and hospitalization rates.   
    The complexity of diabetes therapy on a personal level (number of medications undertaken) 
provides important implications for the safety of patients and quality of diabetes management as 
well as drug cost control.  Documenting the average number of prescriptions and number of drug 
classes by each patient is important for public health concerns with respect to polypharmacy.  
Addressing the socio-economic inequalities regarding multi-pharmacy use and medication 
expenditures provides a better understanding for policy makers on strategies for diabetes 
management. 
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    To our knowledge, however, there has been few study focused on detailed quantification of 
the level of complexity based on the therapeutic drug classes 
[10] [24]
.  The literature gap is 
discussed in Chapter 2.  This study contributes to the literature that quantifies multiple 
therapeutic drug classes used on a patient level and its socio-economic determinants as they 
influence the patterns of patients’ medication utilization. 
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CHAPTER 2 
Literature Review 
 
2.1 Epidemiology of Diabetes 
    Current data show that we have been in the midst of a global epidemic of diabetes. Shaw and 
his colleagues, using the International Diabetes Federation (IDF) data, estimated that 285 million 
adults suffering from diabetes worldwide in 2010.  This means that the global prevalence of 
diabetes is 6.4%, and it is predicted that the prevalence will reach 7.7% among adults by 2030 
[25]
.  
After adjusted for age and gender, the highest regional prevalence for diabetes in 2010 was for 
North America, followed by the Eastern Mediterranean and Middle-East (EMME) and South 
Asia 
[25]
.  The United States has the largest numbers of people with diabetes, followed by India 
and China, the two nations with the largest populations in the world 
[25]
.    
According to the recent report from U.S. CDC, 25.8 million Americans have diabetes and 79 
million adults have pre-diabetes.  Pre-diabetes as defined by the American Diabetes Association 
as a condition in which blood glucose levels are higher than normal but not high enough to be 
diagnosed as diabetes
[2]
.  An estimated 90-95% of diagnosed diabetes is the noninsulin-
dependent type 2 form of the disease which is characterized by insulin resistance, or the inability 
of cells to effectively use insulin 
[1]
.  A report of the National Diabetes Fact Sheet for 2011 
indicated that diabetes affects 8.3% of Americans of all ages and 11.3% of adults aged 20 years 
and above 
[26]
.   
 Geography, age and race affect the prevalence of diabetes.  In the U.S., there is a 
geographically coherent region of 15 southern states called the diabetes belt, where the 
prevalence of diagnosed diabetes is especially high 
[27]
.  The prevalence of diabetes in the 
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diabetes belt was reported as high as 11.7% in 2007-2008 
[27]
, compared to the national 
prevalence of 7.8% in the same year 
[1]
.  Regionally, using the National Health and Nutrition 
Examination Survey (NHANES) database in 2003-2007, Danaei estimated that the lowest 
prevalence of diabetes was in the Midwest and the Northeast with the age-standardized 
prevalence ranging from 11.0% to 12.2% for men and 7.3% to 8.4% for women 
[28]
.  The highest 
prevalence was in the southern and Appalachian states where age-standardized diabetes 
prevalence was 15.8% to 16.6% for men and 12.4% to 14.8% for women 
[28]
.  Danaei also 
reported that age-standardized diabetes prevalence was higher in men than women in all states, 
with the largest differences in Minnesota, Colorado, Utah, and Maine, where prevalence in men 
was 32% to 38% higher than that in women (Figure 2.1)
 [28]
. 
Racial variance in diabetes prevalence in adults has been shown where 7.1% of nonHispanic 
whites, 8.4% of Asian Americans, 11.8% of Hispanics, and 12.6% of nonHispanic blacks have 
diagnosed diabetes in 2007-2009 
[26]
.  Furthermore, compared to nonHispanic white adults, the 
risk of diagnosed diabetes was 18% higher among Asian Americans, 66% higher among 
Hispanics, and 77% higher among nonHispanic blacks 
[26]
.   
The prevalence of diabetes increases with age.  The prevalence of diabetes among individuals 
aged of 20-44, 45-64 and ≥65 years old were 3.7%, 13.7% and 26.9%, respectively (Figure 2.2) 
[2]
.  Compared to younger persons 44 years and younger, older patients over 65 years have more 
than 7 times the prevalence of diabetes.  
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Figure 2.1: Estimated prevalence of total diabetes by state, sex and age group  
(age-standardized to the 2000 U.S. population) 
[28] 
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Figure 2.2: Estimated percentage of people aged 20 years or older with diagnosed and 
undiagnosed diabetes, by age group, United States.  
 (Source: 2005-2008 National Health and Nutrition Examination Survey) 
[2] 
 
 
2.2 Economic burden of diabetes 
The growing number of diabetics and the costs of treatments for the disease and its 
complications have significant economic impact.  The total estimated direct medical costs and 
lost productivity was $174 billion in 2007 in the United States 
[29]
.  Direct medical costs 
attributed to diabetes include hospital inpatient care, diabetes medications and supplies, retail 
prescriptions to treat complications of diabetes, and physician office visits.  Inpatient care 
accounts for 50% of total medical expenditures, followed by diabetes medication and supplies, 
which accounts for 12% 
[29]
.  Indirect costs resulting from lost productivities due to diabetes were 
estimated as $ 58 billion, including absenteeism, reduced productivity while at work for the 
employed population, reduced productivity for those not in the labor force, unemployment from 
disease-related disability, and lost productive capacity due to early mortality.  Averagely, people 
with diagnosed diabetes have medical expenditures that are up to 2.3 times higher than what 
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expenditures would be in the absence of diabetes 
[29]
.  Other factors that are attributable to the 
economic burden of diabetes include higher insurance premiums paid by employees and 
employers, reduced earnings through productivity loss, and reduced overall quality of life for 
patients with diabetes and their families.  On average, a US male diagnosed as having diabetes at 
age 40 years will lose almost 12 life-years and 19 quality-adjusted life-years (QALYs) compared 
with a person of the same age without diabetes.  Similarly, a US female diagnosed as having 
diabetes at age 40 years will lose about 14 life-years and 22 QALYs 
[30]
. 
Indeed, the burden of diabetes is imposed on all sectors of society.  Much of the cost is 
preventable through improved diabetes management, initiated to reduce the prevalence of 
diabetes and costly complications.  
 
2.3 Risk factors for diabetes population 
While the prevalence of diabetes can provide information about the burden of disease in the 
community, prevalence rates do not capture individuals’ risks of developing diabetes.  The 
variation in diabetes prevalence across states, ages and races indicates that diabetes is strongly 
affected by behavioral, cultural, and environmental factors clustered and overlaid on genetic 
susceptibility.  Individual level of risk factors for diabetes include genetic predisposition, 
race/ethnicity, increased body mass index (BMI), physical inactivity, and some medical 
conditions associated with diabetes such as cardiovascular disease and obesity.   
Individuals at higher risk for diabetes include: (1) those with impaired glucose tolerance (IGT) 
and/or impaired fasting glucose (IFG); (2) people over age 45; (3) those with a family history of 
diabetes; (4) people who are overweight; (5) people who do not exercise regularly; (6) people 
with low HDL cholesterol or high triglycerides, high blood pressure; (7) Certain racial and ethnic 
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groups such as NonHispanic Blacks, Hispanic/Latino Americans, Asian Americans and Pacific 
Islanders, and American Indians and Alaska Natives); and (8) women who had gestational 
diabetes, or who have had a baby weighing 9 pounds or more at birth 
[31]
.   
Race is a strong independent risk factor for diabetes.  Diabetes is over twice as prevalent 
among African-American adults as compared to their white counter-parts, with odds ratio (OR) 
=2.35 
[32]
.  Some risk factors such as race, BMI, and socioeconomic status (SES) are associated 
with each other, presenting a combined impact on developing diabetes.  A higher incidence of 
diabetes is reported among African American women in lower SES versus higher SES 
neighborhoods 
[33]
, increased BMI among women in areas of high unemployment relative to 
areas of low unemployment 
[34]
.  For overweight persons whose BMI was between 25-29.9, 
ethnic disparities worsened as diabetes prevalence increased 33% in Whites, compared to 60% in 
Blacks, and 227% in Mexican Americans 
[35]
.  Some investigations also indicate higher rates of 
diabetes in rural areas relative to urban centers 
[36] [37]
, because socioeconomic factors such as 
education, income and health insurance status are strongly related to health and vary between 
rural and urban settings, and these factors contribute to health differences 
[37]
.  Health insurance 
status is important because it is related to income as well as health patterns.  Lower income level 
contributes to a higher proportion of that is uninsured or poorer health insurance overages, 
resulting in lower level of access to the health care services. 
Hence, a variety of factors contribute to the onset and management of diabetes disease, 
including demographic, geographic, socioeconomic factors and clinical information as well.  
Factors such as age, races/ethnicities, education, income, health insurance status, health 
perceptions, and lifestyles have impacts on the disease management and health care service 
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utilization.  Understanding the diabetes epidemic and management must take into account a 
complex array of multiple risks such as individual, social, economic, and environmental factors. 
 
2.4 Diabetes Complications 
The population burden of diabetes complications is large in terms of mortality, morbidity, and 
loss of quality of life.  Diabetes is such a serious disease in that it can results in blindness, kidney 
failure, peripheral neuropathy and arterial disease, cognitive impairment, and death 
[38]
.  The 
pathobiology of diabetic complications is generally featured as hyperglycemia-induced tissue 
damage, shown in Figure 2.3 
[39]
.  Although the damage process can be modified by both genetic 
determinants of individual susceptibility and independent accelerating factors such as 
hypertension, some cell types are particularly susceptible to be damaged by hyperglycemia 
because they are not efficient in reducing the transport of glucose inside the cell when they are 
exposed to hyperglycemia.  These cell types include: capillary endothelial cells in the retina, 
mesangial cells in the renal glomerulus, and neurons and Schwann cells in peripheral nerves 
[39]
.  
Hence, diabetes selectively damages cells such as endothelial cells and mesangial cells.  
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Figure 2.3: General features of hyperglycemia-induced tissue damage 
[39]
 
 
 
2.4.1Morbidity 
The morbidities of diabetes include cardiovascular disease, eye, kidney, and lower-extremity 
disease, acute metabolic complications and disability 
[26] [38]
.  
Cardiovascular disease  
In the United States in 2004, heart disease and stroke were noted on 68% and 16%, 
respectively, of diabetes-related death certificates among people ages 65 years or older 
[26]
.  In 
2005-2008, 67% of adults aged 20 years or older with diabetes had hypertension, which is 
defined as blood pressure greater than or equal to 140/90 mmHg 
[26]
.  The prevalence of ischemic 
heart disease among patients with diabetes varies by age groups.   
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The prevalence rate of heart disease was about 14 times the rate among those without diabetes 
in persons 18 to 44 years of age, 3 times as high in persons 45 to 64 years of age, and almost 
twice as high in those 65 years of age or older 
[38]
.  Other studies have shown that the rates of 
cardiovascular disease in diabetes patients are also different by patients’ gender.  The absolute 
rates are reported to be higher in men than in women, while the relative risk is higher in women 
than in men, comparing those with and without diabetes 
[41] [42]
.  
 
Eye, Kidney, and Lower-Extremity Disease 
    Diabetes retinopathy is the leading cause of new cases of blindness among adults 
[26] [40]
.  A 
cross-sectional study on a nationally representative sample of the National Health and Nutrition 
Examination Survey in 2005-2008 estimated a crude prevalence of diabetic retinopathy and 
vision-threatening diabetic retinopathy was 28.5% and 4.4%, respectively, among older persons 
with diabetes aged above 40 years 
[43]
.  Vision loss due to diabetic retinopathy occurs through a 
variety of mechanisms, including retinal detachment, preretinal or vitreous hemorrhage, 
associated neovascular glaucoma, and macular edema or capillary nonperfusion 
[44]
.  Other cause 
of vision impairment among persons with diabetes include macular edema which is specific to 
diabetes, cataracts and glaucoma that are not specific to diabetes but occur more commonly in 
diabetic than in nondiabetic persons 
[45]-[47]
. 
Diabetes is the leading cause of end-stage renal disease (ESRD), nontraumatic lower-extremity 
amputations (LEAs) as well 
[48]
.  Diabetes is a major cause of chronic kidney disease (CKD) 
[49]
, 
and diabetic nephropathy accounted for 44% of all new cases of end-stage renal disease in 2008 
[26]
.  The precise pathophysiologic basis for the association between deteriorating kidney function 
and diabetes disease is unclear. But it is suggested that poorly controlled glucose levels, blood 
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pressure, and cholesterol activate inflammatory mediators, and patients with a genetic 
predisposition may help progressing to advanced stage nephropathy 
[49]
.   
Lower-extremity disease, which includes peripheral neuropathy and peripheral arterial disease 
or both, results in elevated rates of lower-extremity amputations among persons with diabetes.  
More than 60% of nontraumatic lower-limb amputations occur in people with diabetes 
[26]
.  
People with diabetes have been found to have 2 to 3 times the prevalence of either peripheral 
neuropathy symptoms or insensate feet 
[50]
.   
 
Acute Metabolic Complications 
The acute metabolic complications of diabetes consist of diabetic ketoacidosis (DKA), 
hyperosmolar nonketotic coma (HNC), lactic acidosis (LA) and hypoglycemia 
[51]
.  DKA and 
HNC are related to insulin deficiency resulting in the metabolic outcome of very low levels of 
effective insulin action 
[51] [52]
.  DKA is clinically defined by absolute insulin deficiency with 
hyperglycemia, while HNC is defined by the presence of relative insulin deficiency.  LA is 
usually related to other factors such as cardiovascular diseases, and hypoglycemia mostly results 
from the treatment of diabetes.   
Only the incidence rate of DKA is available from population-based studies.  It is estimated that 
DKA is more common in young diabetic people and may be more common in women than men 
[51]
.  Except hypoglycemia, the other three metabolic complications of DKA, HNC, and LA 
require hospitalization for treatment and thereby result in increased use of health care resources 
and costs. 
 
Nervous System Disease 
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    Diabetic neuropathies are among the most frequent complication of long-term diabetes. About 
60 to 70 percent of patients with diabetes have mild to severe forms of nervous system damage 
[26]
.    The femoral nerve is commonly involved giving rise to symptoms in the legs and arms, 
and pain is the chief symptom that tends to worsen when patients are at rest.  It is estimated that 
almost 30 percent of diabetes patients aged over 40 years old have impaired sensation in the feet 
[26]
.  Furthermore, advanced femoral nerve disease is a major cause of lower extremity 
amputations.   
     
Other Diabetes Complications 
    Other complications such as depression, susceptibility to other illnesses, are found higher rates 
among diabetes patients compared to other population.  Depression is an independent risk factor 
for the onset of type 2 diabetes 
[51]
.  Not only can it complicate diabetes management, but also 
negatively affects the course of diabetes and is associated with increased risk of complications 
[53] 
[54]
.   There has been a growing call to understand the medical and psychosocial challenges that 
highlights the importance of concerning about mental health of the diabetes patients.   
    Besides, diabetes patients are found to be more susceptible to other illnesses, such as 
pneumonia and influenza.  Most of the time, they have worse prognosis than patients without 
diabetes 
[26]
.     
 
2.4.2 Mortality 
Diabetes was the seventh leading cause of death based on U.S. death certificates in 2007 
[2]
.  
This estimate is based on the 71,382 death certificates in which diabetes was the underlying 
cause of death 
[26]
.  Furthermore, diabetes was a contributing cause of death in an additional 
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160,022 death certificates for a total of 231,404 certificates in the same year in which diabetes 
appeared as any-listed cause of death 
[26]
.  Studies also suggested that death certificates 
underestimate the prevalence of diabetes among decedents 
[55]
.   
 
2.5 Goals of drug therapy for Diabetes 
Effective glycemic control is the main goal of diabetes therapy 
[2]
.  However, the nonglycemic 
goals for diabetes management are of paramount importance as well, especially for the 
management for cardiovascular complications because they are the major cause of mortality in 
patients with diabetes 
[18]
.   
 
2.5.1 Glycemic goals 
The recognition of the efficacy in substantially reducing morbidity by achieving specific 
glycemic goals has made the effective treatment of hyperglycemia a priority in diabetes 
management 
[2] [56] [57]
.  Intensive treatment strategies have been demonstrated to reduce 
complications of both type 1 and type 2 diabetes 
[7] [13] [14]
.  The goals of glycemic control are set 
differently by different organizations.  The American Diabetes Association suggested a general 
glycemic goal of lower than 7% in glycated hemoglobin (A1C) level for nonpregnant adults 
[2]
, 
while the American Association of Clinical Endocrinologists (AACE) and the American College 
of Endocrinology (ACE) recommend A1C level of ≤ 6.5% [58].  In general, studies have shown 
that maintaining glycemic levels as close to the nondiabetic range as possible has been 
demonstrated to have a powerful beneficial effect on reducing complications such as retinopathy, 
nephropathy, neuropathy, and cardiovascular disease (CVD) in diabetes patients 
[59]
.    
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Blood glucose-lowering medications are available for both type 1 and type 2 diabetes.  
However, oral blood glucose-lowering medications can only be used for patients with type 2 
diabetes.  These oral medications include sulfonylureas, meglitinides, the biguanide, metformin, 
thiazolidinediones, alpha-glucosidase inhibitors, and the oral dipeptidyl-peptidase-4 inhibitor 
sitagliptin
[60]
.  The increased number of choices available to physicians and patients has 
heightened concern whether used alone or in combination with other blood glucose-lowering 
interventions are most appropriate for the individual patients 
[59] [61]
.   Overall, the ADA and the 
European Association for the Study of Diabetes (EASD) published a consensus statement that 
the main objective of hyperglycemia management is to achieve and maintain glycemic control 
and to change interventions when therapeutic goals are not being met 
[2]
.  
 
2.5.2 Nonglycemic goals 
The nonglycemic goals for diabetes management refers to the prevention and management of 
diabetes complications, among which cardiovascular disease is the major cause of morbidity and 
mortality for diabetes individuals and the largest contributor to the medical costs of diabetes.  
The genesis of cardiovascular complications is in pre-diabetic states, and studies have shown that 
strict glycemic control is effective in preventing and delaying the development of CVD 
[18]
.   The 
CVD treatments include controlling hypertension, elevated low-density lipoprotein (LDL), 
prothrombotic state and cigarette smoking.  The goals of these treatments are listed in Table 2.1, 
according to the ADA statement on standards of medical care in diabetes 2010 
[2] [18]
. 
Other nonglycemic goals include nephropathy, retinopathy, neuropathy treatment and food 
care.  ACE inhibitors or ARBs are recommended for the treatment of the nonpregnant patient 
with albuminuria, which is an early marker of chronic kidney disease (CKD) 
[62]
, and is 
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associated with a higher risk of renal function loss 
[63]
.  The management of painful 
polyneuropathy is focused on symptom relief and positively improving the quality of life 
[2]
.  For 
example, gastroparesis symptoms may improve with prokinetic agents such as metoclopramide 
or erythromycin; medications for erectile dysfunction may include phosphodiesterase type 5 
inhibitors, intracorporeal or intraurethral prostaglandins 
[2]
.   
Table 2.1 Treatment goals for CVD in adult diabetes patients 
[2] [18] 
Hypertension/blood pressure control < 130/80 mmHg 
Dyslipidemia control 
LDL cholesterol: < 100mg/dL 
HDL cholesterol: >50 mg/dL 
Triglycerides: < 150 mg/dL 
Prothrombotic state control 
Aspirin therapy: 75-162 mg/day as primary prevention 
strategy in adult diabetes patients and macrovascular 
disease or for primary prevention in patients older 
than 40 years with diabetes or with more than one 
other CVD risk factor. 
Cigarette smoking goal Cessation 
 
 
2.6 Polypharmacy Regimen for Diabetes and Literature Gap 
Most diabetes patients take oral medications instead of insulin to control glucose level.  It is 
estimated that only 12% adult patients with diabetes take insulin only, while 58% take oral 
medication only (Figure 2.4) 
[26]
.   
Polypharmacy can be defined as the use of two or more medications simultaneously 
[20]
.  The 
characteristics of diabetes and its complications often require a multiple medication regimen for 
diabetes, frequently using drugs from multiple therapeutic classes.  However, the risks of 
polypharmacy and the potential inappropriate medication use must be considered and balanced 
against the benefits of multiple drug therapies.  Simultaneous use of multiple medications is 
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often associated with drug-drug interactions, adverse drug reactions, medication errors, and 
increased risks of nonadherence to therapeutic regimens and higher hospitalization rates, 
especially for elderly patients who are suffering from decreased renal and hepatic functions 
[20]-
[23]
.   
 
Figure 2.4 Percentage of adults with diagnosed diabetes receiving treatment with insulin 
or oral medication, United States, 2007-2009 
(Source: 2007-2009 National Health Interview Survey) 
[26] 
 
Surprisingly, although the risks of multiple medication use are well recognized, most studies 
on polypharmacy have merely focused on the levels of adherence to the medication therapy 
[19] 
[64] [65] 
and the association between the adherence level and clinical control of LDL, A1C, and 
blood pressure level 
[66] [67]
.  An inverse relationship was evidenced between the number of drugs 
prescribed and patients’ adherence to diabetes-related medications, resulting a significantly 
lower A1C and total cholesterol level at the end of the study period 
[19]
. Successful control of 
clinical targets depended highly on a subject’s baseline number of treatments. The number of 
medications among successful cases was 11 to 17 percentages lower than those failed to achieve 
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the clinical targets 
[67]
. However, these studies have typically not characterized the drug regimens 
in terms of a detailed description of therapeutic drug classes used to treat patients with diabetes.   
 Grant et al provided evidence that treatment related to diabetes care has grown more complex 
over time 
[24]
.  Using the National Ambulatory Medical Care Survey (NAMCS), they 
characterized trends in the number of prescribed medicines, management of hyperglycemia, 
hypertension, and hyperlipidemia from 1991 to 2000.  Significant increases were found in the 
number of prescription medicines reported at office visits over time (Figure 2.5).  The unadjusted 
proportion of patients prescribed at least 5 medications increased in a linear trend from 18.2% in 
1991 to 29.9% in 2000 (p<0.001), as shown in Figure 2.5.  After controlling for age, gender, 
race/ethnicity, insurance status, physician type, the diabetes type and visit duration,  the 
proportion of patient visits with 5 or more medicines increased by 10.1% per year from 1991 to 
2000 (95% CI, 6.6%-13.5%; p < 0.001).   
 
 
Figure 2.5 Trends in the total number of prescribed medicines, 1991-2000 
[24] 
 
Increases were also found in the use of medications for antihypertension and lipid level 
lowering (Figure 2.6).  In similar regression models controlling for patient and physician 
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characteristics and visit duration, the proportion of prescribing antihyperglycemia medications 
did not change significantly (p>0.05), but that of prescribing antihypertension and 
antihyperlipidemia medications resulted in significant increases, with an increase of 12.9% and 
19.1% per year, respectively. 
 
Figure 2.6 Trends in pharmaceutical treatment of hyperglycemia, hypertension, and 
hyperlipidemia, 1991-2000 
[24]
 
 
However, this study was not able to provide a basic description of trends in the number of 
medications used by diabetes patients. The unit of the analysis was the visit instead of the patient, 
so the medication care at an individual level was not assessed.  Furthermore, the study placed a 
cap on the total number of medications (5 medications) for each visit, so the average number of 
medications was not determined.   
Huang et al assessed the trends in diabetes regimens from 1995 to 2003, using 30 managed 
care plans in Midwest and Southern regions 
[10]
.  To evaluate the complexity of medication 
regimens, they calculated the average number of medications and the proportion of patients 
receiving diabetes-related medications (blood glucose, blood pressure, and cholesterol control 
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agents).  On a patient level, they noted a significant increase in the average total number of 
diabetes-related medications among patients with prescribed medications (from 2.96 to 3.70, 
p<0.01), with smaller increases seen for glucose lowering (from 1.45 to 1.65, p<0.01) and blood 
pressure lowering regimens (from 2.14 to 2.51, p<0.01).  Regarding the proportion of patients on 
the three types diabetes-related medications, they reported a dramatic rise in the proportion on 
cholesterol lowering (18% to 39%, p<0.01) and antihypertension agents (51% to 62%, p=0.04), 
adjusted for age, age-squared, female and interactions of female with age variables (Figure 2.7) 
[10]
.   
Compared with Grant’s study, Huang assessed the average number of medications and 
percentage of patients using three major drug categories of diabetes regimen.  Nevertheless, the 
results of this study could not be generalized to the whole country because the study sample was 
not nationally representative.  Besides, only three diabetes-related drug classes (cholesterol 
lowering, antihypertension and glucose lowering agents) were taken into account in this study.  
Even though cardiovascular diseases are important complications of diabetes, there are more 
treatments for diabetes patients in order to take care of other complications such as depression, 
neuralgia and kidney diseases. Thus, the complexity of regimen for diabetes patients needs to be 
comprehensively assessed.  Moreover, they did not access to the actual risk factor levels, such as 
geographic, demographic, health insurance status, and other socio-economic factors.  Our 
knowledge is sparse with respect to identifying individuals who are particularly prone to 
polypharmacy therapies.  Overall, we do not know the extent of complexity of the regimens and 
financial burden of medical therapy in diabetes patients. 
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Figure 2.7 Adjusted trends in (A) the proportion of patients with any or specific types of 
diabetes drugs, and (B) the total number of diabetes related drugs conditional on any use of 
drugs 
[10] 
 
Based upon the prior literature, this study uses a recent and nationally representative dataset.   
The therapeutic drug classes among diabetes patients are broadened from 3 to top ten categories 
that are used among diabetes patients on patient level.  Individual factors that have impacts on 
diabetes regimen and drug expenditures are evaluated as well, so as to give an extensive 
understanding of the complexity of diabetes treatment.  The factors affecting individual’s 
medication use and drug expenditure are discussed in Section 2.7. 
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2.7 Socio-economic predictors of medication use and expenditure 
Within the multicultural context of the United States, inequalities in health services utilization 
and consumption is a concern in this country.  Differences in drug use and expenditures are 
based on race/ethnicity, gender, age, income, insurance status, geographic location, sexual 
orientation, occupation, or health behaviors.  Disparities among the different segments of the 
population have been defined in terms of differences in health status, risk factors for disease and 
injury, access to and use of health care services, access to health insurance, and differences in the 
quality of care received 
[68]
.   Reasons for the inequalities in health care included differences in 
risk factors, lack of access to health care, inadequately targeted prevention messages, and 
cultural differences.   
In the United States, the first national report on health care quality and disparity was released 
by the Agency for Healthcare Research and Quality (AHRQ) in 2003.  It demonstrates a broad 
picture of the scope and characteristics of differences in health care quality and access associated 
with patient gender, age, race, ethnicity, income, education, and location 
[69] [70]
.  They reported 
that racial and ethnic minorities and poor people often receive poorer quality of care and face 
more barriers when trying to access health care 
[70]
.   
In this study, we focus on the demographic, geographic and related socio-economic variants in 
prescribed medication use and spending among adult patients with diabetes.  These factors are 
overlapped and influence each other.  
 
2.7.1 Demographic variants 
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The United States is an ethnically and racially diverse nation.  The current population is 
approximately 67% nonHispanic White, 12% black, 14% Hispanic, 1% American Indian/Alaska 
Native, and 4% Asian (Figure 2.8) 
[71]
.   
 
Figure 2.8 Percentage of United States population, 2005 
[71] 
 
There have been abundant studies reporting that racial/ethnic minorities and poor people use 
fewer medications and poorer quality of heath care.  Compared with whites, nonwhites including 
African Americans, Latinos, and Asian/Pacific Islanders often have poorer glycemic control 
[72]
.  
Another study reported that the rates of medication underuse were highest among African 
Americans and Latinos 
[73]
.  The current proposed mechanisms for racial/ethnic disparities in 
medication use are physiologic, socioeconomic, cultural in nature.  The median family annual 
income for nonHispanic Whites and Asians is $20,000 to $25,000 higher than for Blacks, 
Hispanics, and American Indians/Alaska Natives in 1999 
[71]
.  Hence, patients with higher 
education and income are able to purchase better health insurance coverage and to obtain more 
access to and high quality of healthcare services.  The Hispanic population is estimated to be 
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much younger on average than the other demographic groups, with a median age of 25.8 years 
compared with 38.6 years for the white population in 2000 
[71]
.  As a result, it is likely that 
Hispanics consume less health care than other groups and are underrepresented in research on the 
use and quality of health care.  Besides, social determinants such as cultural beliefs in drug 
regimens and medical conditions may result in differences in medication adherence. 
Gender may contribute to the difference in medication utilization and consumption. The 
imbalance between men and women exists with respect to health care utilization related costs.  In 
general, women tend to use significantly more health care services and spend more health care 
dollars than men 
[74].  An analysis of Express Scripts’ integrated database of medical and 
pharmacy claims demonstrated that women contribute to 60% of medical spending and consume 
59% of the prescription volume 
[75]
.   
Age has notable impacts on medication use as well.  Elderly patients have higher risks of 
complications and side effects of medications due to their decreased liver and renal functions 
[20] 
[76]
.  Diabetes is such a chronic disease that the normal aging process can change the way 
medication are absorbed, metabolized and distributed in the body.     
 
2.7.2 Geographic variants 
Geographic factors influence not only the prevalence and incidence of diabetes, but the 
medication use among diabetes patients as well.  Rural residents have disparities in access to care 
compared with urban residents because of distance to health care facilities 
[77]
.  The impacts of 
geographic factors on medication use may overlap with that of race/ethnicity.  Since Blacks or 
Hispanic populations tend to live in different areas from nonHispanic white populations, location 
matters in the measurement of health care disparities.   
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In this study, both geographic region and metropolitan statistical area (MSA) status are 
included to predict the variation in drug use and spending among adult diabetes patients. 
 
2.7.3 Impacts of health insurance coverage 
    Health insurance coverage is an important determinant for medication use and spending, and it 
is strongly related to better clinical outcomes as well 
[78]
.  Health insurance status reflects a 
variety of social and economic status of the patients.  Income level, employment status, 
citizenship status, and language play roles in disparities in insurance coverage, and thus impacts 
the access to care and quality of care 
[79]
.   
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CHAPTER 3 
Methodology 
 
3.1 Data Source 
    The data used in this study were derived from the 2006 Medical Expenditure Panel Survey 
(MEPS) Full Year Consolidated Data Files and the 2006 MEPS Prescribed Medicines (PMED) 
Files.  The datasets were obtained from their official website which is maintained and co-
sponsored by the Agency for Healthcare Research and Quality (AHRQ) and the National Center 
for Health Statistics (http://www.meps.ahrq.gov/mepsweb/).   
MEPS, which was initiated in 1996, is a nationally representative longitudinal survey of 
families and individuals, their medical providers (doctors, hospitals, pharmacies, etc.), and 
employers across the United States 
[80]
.  MEPS is a survey of panel design, which is featured by 
five rounds of interviews covering two full calendar years 
[81]
.  The survey collects detailed 
information on health care utilization and expenditures, health insurance, and health status, as 
well as a variety of social, demographic, and economic characteristics for the civilian 
noninstitutionalized population.  MEPS consists of two major components: household 
component (MEPS-HC) and insurance component (MEPS-IC). MEPS-HC collects data for each 
person on demographic characteristics, health conditions, health status, health insurance 
coverage, income, and employment.  MEPS-HC data are available on MEPS Web site in data 
tables.  MEPS-IC, which is also known as the health insurance cost study, collects data including 
the types of private insurance plans offered, premiums, contributions by employers and 
employees, and benefits associated with these plans. However, IC data files are not available for 
public release.  In this study, we only used MEPS-HC data file. 
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Two data files were used from the household component: 2006 Full Year Consolidated Data 
File and 2006 Prescribed Medicines File. Data were obtained in Rounds 3, 4, and 5 of Panel 10 
and Rounds 1, 2, 3 of Panel 11, covering calendar year 2006, as illustrated in Figure 3.1.   
 
Figure 3.1: Survey rounds for MEPS panels covering calendar year 2006 
[81] 
 
The consolidated data file contains 1672 variables, pertaining to survey administration, 
demographics, employment, health status, disability days, quality of care, patient satisfaction, 
health insurance, income and person-level medical care use and expenditures. About 34,145 
persons participated in MEPS Household Component of medical expenditure panel survey in 
2006 
[81]
.  This count includes all household survey persons who resided in eligible responding 
households.  Of these persons, 32,577 persons were assigned a positive person-level weight.  In 
this study, only the observations with positive person-level weight are used in the analysis.  
Observations with zero person-level weights were deleted. 
    In the prescribed medicine file, counts of prescribed medicine utilization are based entirely on 
household reports. Persons with no prescribed medicine use for 2006 are not included on this file.  
The prescribed medicine dataset contains 341,994 records of prescribed medicine.  Of these 
prescribed medicine records, 336,109 records are associated with persons having positive 
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person-level weight.  Diabetic supplies, such as syringes and insulin, are also included in the data 
of MEPS prescription drug expenditure and utilization. Each record on the prescription file 
includes an identifier for each unique prescribed medicine, national drug code (NDC), medicine 
name, selected Multum Lexicon variables, total expenditure and sources of payments.  Multum 
Lexicon variables are derived from Multum Lexicon database at Cerner Multum. Inc, which is a 
global company, providing updated databases for drug information. We used Multum Lexicon 
variables to identify the drug classes that are used among the sample population. 
In this study, the two data files were merged with each other by linking the unique person 
identifier, variable DUPERSID.  By using the person-level weight variable (PERWT06F), the 
analyses were able to make estimates for the civilian noninstitutionalized U.S. population for 
2006. 
 
3.2 Study Sample 
The study sample was nonpregnant diabetes patients who are older than 18 years of age.  
Patients were eligible for inclusion based on their answers to whether they have ever been 
diagnosed with diabetes (ICD-9-CM codes 249, 250) 
[81]
.  Patients with gestational diabetes were 
excluded.  A total of 2,189 patients claimed to have been diagnosed as diabetes.  These patients’ 
demographic information from consolidated data file was then linked with their prescribed 
medication records from prescribed medicine data file for analyses.  
Information from the last rounds of Panel 10 and Panel 11 in the year 2006, in order to obtain 
the most accurate number of patients who have diabetes.  Using the previous rounds information 
may exclude those patients who potentially have diabetes but were not diagnosed during the 
earlier rounds. 
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Due to the dataset limitation, we were not able to differentiate between patients with Type 1 
and Type 2 diabetes.  Albeit we were able to exclude part of the Type 1 diabetics by limiting 
only adult patients included in this study, we may still have some Type 1 diabetes who used 
insulin only without other oral anti-diabetic medications in our sample.  Thus our estimates on 
medication use may be underestimated. 
 
3.3 Variables 
    The MEPS database contains a wide range of demographic and clinical variables for analysis.  
These variables include age, gender, race, geographic region, metropolitan statistical area (MSA), 
marital status, education year, family income as percent of poverty line, family size, insurance 
coverage status, health perception, medical condition, medication use, and medication 
expenditure.  
Categorical variables were created for some demographic information such as age groups, 
race/ethnicity, marital status, insurance coverage status, health perception and co-morbid 
diseases. For age groups, patients were divided into three categories: 18-44, 45-64 and 65-85 
years of age, according to the age categorization of ADA 
[2]
.  Medication use among diabetic 
patients is age-related due to the progress of diabetes disease and complications.  Patients over 
65 years old are more likely to use multiple medications than younger individuals 
[20] [62]
.  For the 
race/ethnicity variable, the study sample was categorized into seven groups: White Hispanic, 
White nonHispanic, Black, Asian, American Indian, Hawaiian and multiple races. Hispanic 
Nonwhite patients were differentiated from Hispanic White individuals on account of the fact 
that Hispanics share distinguished cultural beliefs, habits, income level, and education level from 
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nonHispanic population. These racial/ethnic differences may contribute to variance in 
medication use among diabetes population.   
The variable of health insurance coverage was categorized into Medicare Part D, Medicare 
nonpart D, Medicaid, Private insurance coverage, and self-payers.  Each patient was assigned to 
only one category of insurance type.  A hierarchy according the primary payer was used for 
people who enjoyed coverage from more than one source.  Medicare coverage had first place in 
this hierarchy.  For instance, if a person was covered by Medicare and Medicaid or private 
insurance, he or she was categorized as having Medicare coverage regardless of any other 
coverage, because Medicare is the primary payer for his or her drug benefit.   Same as other 
example, if someone had both Medicare non-Part D and private insurance, then the person was 
classified as having private insurance group as his primary payer is private insurance.  The other 
two categorical variables that were created in this study were general health perception and co-
morbid diseases.  Both of these two clinical factors contribute to a variation in medication use 
and thus affect drug spending.  Patients with poor health perception and more co-morbid diseases 
are more likely to experience polypharmacy. 
Two indicator variables (family size, education year) were created to identify people who lived 
alone and who received at least a high school education.  Family size and education are 
associated with medication compliance.  Patients who live with their families have better 
adherence to their medications.  Well-educated people are considered to have better knowledge 
about the therapeutic regimen and may enjoy higher income as well 
[71]
.  Hence, people who live 
with families and well educated are more likely to be adherent to prescriptions.   
Twelve independent variables were used in a multivariable regression model to assess the 
impacts on the three study outcomes of medication use and costs (Table 3.1).  As for the 
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variables of health perception and comorbidites, only the information from the last rounds of 
Panel 10 and 11 (Figure 3.1) was used.  As explained before, the health status and co-morbid 
diseases are progressing over time. In order to avoid the potential changes in health status and 
progress of comorbid diseases during the year, the information obtained at the end of the year 
was used in this study. The 12 independent variables and 3 dependent variables are listed in 
Table 3.1.  In multivariate regression model, the largest group in each independent variable was 
set to be the reference group.   
Table 3.1 –Variables in multivariate model 
Variables Descriptions 
Independent variables 
Age 18-44, 45-64, 65-85 
Gender Male, Female 
Race 
White Hispanic, White nonHispanic, Black, Asian, American 
Indian, Hawaiian, Multiple race 
Region Northeast, Midwest, West, South 
MSA status MSA, NonMSA 
Marital status Married, Widowed, Divorced, Separated, Never married 
Family size =1, >1 
Education Year ≤11 years, ≥12 year 
Family income as percent of 
poverty line  
Poor/negative, Near poor, Low income, Middle income, High 
income 
Health Insurance Coverage 
Medicare part D, Medicare nonpart D, Medicaid, Private 
insurance coverage, Self-pay 
Health Perception Excellent, Very good, Good, Fair, Poor 
Comorbidities 
Asthma, High cholesterol, Angina, Coronary heart disease, 
Heart attack, Other heart disease, Stroke, Arthritis, 
Emphysema, High blood pressure 
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Dependent variables 
Total drug costs per person per year 
Out-of-pocket payment per person per year 
Number of therapeutic drug classes used per person per year 
 
3.4 Identification of Top Ten Therapeutic Classes  
Top ten therapeutic drug classes in total utilization with greatest number of prescriptions were 
identified among our study sample.  The therapeutic classes have been identified by the Multum 
Lexicon variable: TCnSn, a therapeutic sub-classification variable 
[82]
.  As explained in the 
documentation for MEPS prescribed medicine file, the Multum Lexicon variables are derived 
from the Multum Lexicon database at Cerner Multum, Inc, which is a leading global company 
providing information management in healthcare 
[83]
.  Drugs are organized into three levels: 
therapeutic level (TCn), pharmacological level (TCnSn), and specific drug category level 
(TCnSn_n)
 [82]
.   The variable TCnSn is a sub-classification variable of TCn, assigning one or 
more sub categories to a more general therapeutic class category and sub-category given to a 
drug.  For example, the TCn level category includes general therapeutic classes such as anti-
infectives, then it is subdivided into pharmacological classes such as cephlosporins, penicillins, 
quinolones. Cephlosporins can be further subdivided into specific drug categories such as first to 
fourth generation cephlosporins (Figure 3.2). 
37 
 
 
Figure 3.2 Example of Multum drug classification 
 
3.5 Outcomes of Interest 
This study aimed to assess the medication use and expenditure among diabetes patients in the 
year 2006. Medication use was defined at two levels: number of prescription filled and 
therapeutic drug class used in the defined year.  At the prescription level, medication utilization 
was defined by prescriptions filled over the course of the year.  At the therapeutic drug class 
level, medication use was defined as one or more purchases of a medication in a therapeutic class 
of the top ten drug classes.  For this purpose, the assessed outcomes include: (1) the yearly 
average number of prescriptions filled per person; and (2) the yearly average number of drug 
classes used per person. 
Medication expenditures were assessed with respect to (1) total drug cost per patient, and (2) 
out-of-pocket (OOP) spending per user. Out-of-pocket spending refers to the amounts paid by 
individual patients other than any insurance sponsors. Premiums for insurance were not included 
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in OOP calculations in this study.  Total drug cost included all payments by individuals (out-of-
pocket payments), private insurance, Medicaid, Medicare, and other types of insurance.  
Taking into account the risk factors in the prevalence of the diabetes as well as the patterns of 
drug use, socio-economic variables were evaluated in medication use of top ten drug classes and 
medication expenditures at the personal level.  As introduced before, 12 independent variables 
were included in the multivariate regression model to examine the effects of each included factor 
on the outcomes of (1) total drug cost, (2) out-of-pocket, and (3) number of therapeutic drug 
classes used on an the patient level (Table 3.1).   
 
3.6 Statistical Analysis 
The top ten drug classes in utilization among diabetes patients were identified by sorting the 
number of prescriptions for each therapeutic drug class. We conducted descriptive analysis in 
evaluating medication utilization and expenditure on a patient level.  For the drug expenditure, 
we calculated the averages of total drug cost, out-of-pocket spending per person per year.  The 
total annual drug spending was charted for the top ten drug classes in 2006.  The drug utilization 
per person per year was calculated based on the number of prescriptions and number of drug 
classes used by each patient.  The percentages of patients using the top ten drug class were also 
calculated for each therapeutic class.   
Generalized linear modeling (GLM) was used to conduct the multivariate regression. We had 
three dependent variables in terms of the drug spending (total spending and OOP) and top ten 
drug classes utilization. Due to the positively skewed distributions of the outcomes, we used a 
generalized Gamma distribution with a log link to fit the model, in order to obtain more unbiased 
estimates of the impact of the set of predictors 
[84]
.  In the statistical model selection, the model 
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with a log link was superior to those with other functions of link such as reciprocal because it 
came out with the smallest deviance value, based upon the same degrees of freedom.  In 2001, 
Manning and Mullahy suggested that the ordinary least square (OLS) estimates can be notably 
less precise and biased than some of the GLM alternatives, when the distribution is not bell-
shaped or a skewed bell-shaped 
[84]
. Furthermore, the interpretation of the results is relatively 
straightforward using GLM, compared to OLS with log transformation. 
To illustrate, the formula used in this study is shown below.  The response variable Y is 
linearly associated with values of the explanatory variables by: 
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where the e stands for the error term, while the relationship in the generalized linear model with 
log link is: 
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where muy stands for the expected value of Y.  The log link function links the expected values of 
Y to the regressors and determines the model. 
All the data were weighted to reflect the drug utilization and expenditure of the whole 
population in the United States.  Stata 10 was used to conduct all the analyses, using significance 
level of 0.05.   
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Chapter 4 
Results 
 
4.1 Study population 
A total of 2,189 patients were identified in this study, representing 17.5 million diabetes 
patients in the United States in 2006.  The mean age of patients was 63 years of age, 56.01% of 
the patients were women, and 49.06% were White-NonHispanic (Table 4.1).  The majority of the 
study population was elderly patients, given that only 14.62% of the patients were younger than 
45 years old.  In our study sample, there were 12 patients who were diagnosed with diabetes but 
did not have any purchase records of prescription medicines.  However, in order to obtain an 
accurate number of diagnosed diabetes patients and medication use patterns, these 12 patients 
were included into our analyses.   
 
Table 4.1 - Population Characteristics  
Patient Characteristics 
Unweighted 
Frequency (%) 
Weighted Frequency (%) 
Age   
≤44 320 (14.62%) 2,370,273.09 (13.51%) 
45-64 1,043 (47.65%) 8,424,204.89 (48.03%) 
≥65 826 (37.73%) 6,745,717.32 (38.46%) 
Gender   
Male 963 (43.99%) 8,651,271.02 (49.32%) 
Female 1,226 (56.01%) 8,888,914.27 (50.68%) 
Race   
White-Hispanic 501 (22.89%) 2,255,218.19 (12.86%) 
White-NonHispanic 1,074 (49.06%) 11,352,405.40 (64.72%) 
Black 468 (21.38%) 2,672,013.36 (15.23%) 
Asian 74 (3.38%) 566,821.59 (3.23%) 
American Indian or Alaska 
Native 
32 (1.46%) 324,642.65 (1.85%) 
Multiple Races 27 (1.23%) 243,241.93 (1.39%) 
Native Hawaiian or Pacific 
Islander 
13 (0.59%) 125,852.23 (0.72%) 
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Patient Characteristics 
Unweighted 
Frequency (%) 
Weighted Frequency (%) 
Region   
Noreast 333 (15.21%) 3,210,862.52 (18.31%) 
Midwest 412 (18.82%) 3,698,500.68 (21.09%) 
South 897 (40.98%) 6,968,094.42 (39.73%) 
West 547 (24.99%) 3,662,737.66 (20.88%) 
MSA status   
Non-MSA 480 (21.93%) 3,737,994.14 (21.31%) 
MSA 1,709 (78.07%) 13,802,201.10 (78.69%) 
Education year   
≤11 798 (97.06%) 4,741,580.24 (27.32%) 
≥12 1,355 (62.94%) 12,611,139.80 (72.68%) 
Marital status   
Married 1,232 (56.28%) 10,378,177.10 (59.17%) 
Widowed 371 (16.75%) 2,768,054.92 (15.78%) 
Divorced 336 (15.35%) 2,658,680.2 (15.16%) 
Separated 60 (2.74%) 379,034.63 (2.16%) 
Never married 190 (8.68%) 1,356,248.42 (7.73%) 
Family size   
=1 491 (22.43%) 4,088,380.98 (23.31%) 
>1 1,698 (77.57%) 13,451,814.30 (76.69%) 
Poverty level   
Poor 451(20.60%)        2,315,372.80 (13.20%) 
Near poor 196 (8.95%)        1,137,674.62 (6.49%) 
Low income 405 (18.50%)        2,794,879.61 (15.93%) 
Middle income 584 (26.68%)        5,203,709.76 (29.67%) 
High income 553 (25.26%)       6,088,558.49 (34.71%) 
Health Insurance Coverage   
Medicare part D 594 (27.14%) 4,215,645.81 (24.03%) 
Medicare nonpart D 408 (18.64%) 3,815,136.68 (21.75%) 
Medicaid 203 (9.27%) 1,087,827.44 (6.20%) 
Private insurance coverage 696 (31.80%) 6,852,033.68 (39.06%) 
Self-pay 288 (13.16%) 1,569,551.68 (8.98%) 
General Health Perception   
Excellent 99 (4.52%) 921,799.06 (5.26%)  
Very good 373 (17.04%) 3,443,171.32 (19.63%) 
Good 778 (35.54%) 6,324,391.18 (36.06%) 
Fair  645 (29.47) 4,806,581.64 (27.40%) 
Poor 293 (13.39) 2,037,142.09 (11.61%) 
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4.2 Top ten therapeutic classes 
The top ten drug classes in utilization among diabetes patients were: antihyperlipidemic agents, 
angiotensin converting enzyme inhibitors (ACE Inhibitors), beta-Adrenergic blocking agents, 
calcium channel blocking agents, diuretics, antihypertensive combinations, analgesics, 
antidiabetic agents, antidepressants, and proton pump inhibitors.   
 
4.3 Annual drug utilization 
On average, a diabetes patient had 45.34 (median=36) prescriptions (Table 4.2), and 3.43 
(median=3) classes of drugs within the top ten drug classes (Table 4.3).  However, the 
distribution of prescription counts was skewed.  The maximum number of prescriptions was as 
high as 253 per person per year, using all of the top then drug classes throughout the year (Figure 
4.1 and Figure 4.2).  
 
Table 4.2 – Description of number of prescription per person in 2006  
Mean Min 25% 50% 75% Max 
45.34 1 18 36 61 253 
 
 
 
 
Table 4.3 – Description of number of drug classes used per person in 2006  
Mean Min 25% 50% 75% Max 
3.43 0 2 3 5 10 
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Figure 4.1 Distribution of number of prescription used per person per year 
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Figure 4.2 Distribution of number of drug classes used per person per year 
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Regarding the top ten drug classes, about 83.9% of the patients used antidiabetic agents in 
2006, and 52.6% used antihyperlipidemic agents, followed by analgesics, ACE inhibitors and 
Beta-blockers, with percentage of 39.6%, 37.4%, and 28.3%, respectively.  Details are shown in 
Figure 4.3. 
 
 
Figure 4.3 - Percentage of Patients Using the Top ten Drug Class in 2006 (Weighted) 
 
 
4.4 Annual drug expenditure 
On average, a diabetes patient incurred a total of $3,161 (sd = 4235.1) for prescribed 
medicines and spends $1,061 (sd = 1323.43) for out-of-pocket costs annually in 2006.  The top 
ten categories accounted for 61.4% of the total drug spending for diabetics.  Figure 4.4 shows 
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weighted annual total spending of the top ten drug classes.  Antidiabetic and Antihyperlipidemic 
agents were the top two drug classes that cost the most, accounting for 24.1% and 13.5% of the 
total annual drug expenditure, respectively.  
One outlier in the sample had 253 prescriptions used that cost a total of $117302.5.  Out-of-
pocket spending for this patient was $20076.29.  This total was verified and the cause appeared 
to be due to significant analgesic use.  This outlier was kept in the sample because the patient 
was alive on the last day of the study period and met the requirements for inclusion. 
 
Figure 4.4 – Annual total expenditure of top ten drug classes in 2006 (Weighted)  
(Note: the numbers on the top of the bars are the percentage of each drug class spending 
out of total drug expenditure) 
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4.5 Multivariate regression analysis outcomes 
    Tables A-1to A-3 (Appendix) show the results from multivariate regressions.  Race, marital 
status, and health insurance coverage were significant predictors in total drug spending among 
diabetes patient in year 2006.  Compared to White-NonHispanic people, Asians spent 42% less, 
American Indians/Alaska Natives 39% less, and Native Hawaiians/Pacific Islanders 65% less 
total drug spending, all with p <0.05.  Compared to married people, separated individuals spent 
45.9% less on drugs, p=0.009.  Differences in drug spending are also revealed with respect to 
health insurance coverage status.  Compared to patients with Medicare Part D, patients with 
Medicare NonPart D, Private insurance coverage and those without drug coverage had lower 
total drug spending, accounting for 17%, 48%, and 74% less spending, respectively, each with 
p<0.01.  
    Out-of-pocket spending was associated with age, gender, race, and health insurance coverage 
among diabetes patients (Table A-2).  Compared to elderly patients over 65 years, patients 
younger than 44 years old had 30.9% lower OOP payment (p=0.017), but patients between 45 
years old and 64 years did not have significant difference in OOP payment from older adults.   
Males spent 14% less OOP than female patients, with p=0.016.  Asians, American 
Indians/Alaska Natives, and Native Hawaiians/Pacific Islanders had lower OOP payment than 
White NonHispanic people.  Asians were 61% lower, American Indians/Alaska Natives were 
51% lower, people of multiple race background were 49% lower, and Native Hawaiians/Pacific 
Islanders were 97% lower than the comparison group, respectively, all with p<0.05.  For health 
insurance coverage, self-payers spent 40.89% more OOP than Medicare Part D beneficiaries 
(p=0.003), while Medicaid beneficiaries had 26.5% lower OOP payments compared with 
Medicare Part D enrollees.   
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Regarding the number of top ten drug classes used per person per year, predictors of age, 
gender, race, and health insurance coverage showed significant variances among diabetes 
patients (Table A-3).  Compared with older adults over 65 years, patients younger than 44 years 
old used 10.6% fewer drug classes, while patients between 45 to 64 years old used 9.09% more 
drug classes, both with p<0.05.  Male patients used 5.3% fewer drug classes than females, 
p=0.016.  This is supported by findings that females tend to use more medicine than males 
[74] [75]
.  
Compared to White NonHispanic patients, White Hispanics used 9.2% fewer drug classes, p = 
0.008.  Regarding health insurance coverage, not surprisingly, patients with private insurance 
and those without drug coverage used fewer drug classes than patients with Medicare Part D, 
20.7% and 33.2% fewer, respectively, p<0.001, holding everything else constant.  The number of 
drug classes used by patients was associated with the total drug costs and out-of-pocket 
payments. Patients without drug insurance tend to use fewer drug classes, spent less on total drug 
spending but had to pay more by themselves than Medicare Part D beneficiaries.  Private 
insurance beneficiaries spent less on total drug spending, took fewer medications than Medicare 
Part D beneficiaries, but their out-of-pocket payments did not have significant difference.  
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Chapter 5 
Discussion 
 
5.1 Main findings 
Diabetes is a progressive and complex metabolic disorder with a set of complications that 
make it necessary to undertake polypharmacy for patients.  In this nationally representative 
cross-sectional study, we identified the top ten drug classes used most by diabetes patients.  
These drug classes include Antihyerlipidemic agents, Angiotensin converting enzyme inhibitors 
(ACE Inhibitors), Beta-Adrenergic blocking agents, Calcium channel blocking agents, Diuretics, 
Antihypertensive combinations, Analgesics, Antidiabetic agents, Antidepressants, and Proton 
pump inhibitors.  This finding is in line with the strategies of prevention and treatment of 
diabetes and diabetes-related complications such as vascular and neuropathic diseases.  
Among the top ten therapeutic drug classes, antidiabetic agents were used by 83.9% of 
diabetes patients, and accounted for 24.1% of the total spending on drugs among diabetics in 
2006.   Antidiabetic medications, also called antihyperglycemic agents, treat diabetes mellitus by 
lowering blood glucose levels.  Generally, patients are required to undertake monotherapy or 
combination of antidiabetic agents in order to achieve the goal of blood glucose lowering to a 
clinically safe range, as recommended by the clinical guidelines 
[2]
.  A large body of evidence 
have demonstrated that combination therapy appear to be more effective than monotherapy in 
glucose control 
[85] [86]
.   Traditional antidiabetic agents include sulphonylureas, biguanides, 
thiazolidinediones, meglitinide analogues, and alpha-glucosidase inhibitors, that control 
hyperglycaemia through one or more sites of action 
[76]
.  Newer drugs mimic or potentiate the 
activities of incretin hormones, including GLP-1 (glucagon-like peptide-1) mimetics and DPP-4 
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(dipeptidyl peptidase-4) inhibitors 
[18]
.  Despite the benefits of combination therapy of glucose 
control, concurrent use of multiple pharmaceuticals of this drug class may raise the risk of 
adverse effects of poor adherence and drug-drug interactions, especially for drugs that are 
metabolized by the cytochrome P450 (CYP450)  system For instance, it has been confirmed that 
thiazolidinediones (TZD), meglitinide analogues, and sulphonylureas are subject to potentially 
interfere with drugs metabolised with the CYP450 system 
[87] [88]
, and may lead to worse 
outcomes of cardiovascular complications 
[89]
.  
Antihyperlipidemic agents are another major group of medications for diabetes patients, 
ranking second amongst the top ten therapeutic drug classes in utilization and expenditure for 
patients in 2006.  Diabetes patients tend to have a characteristic dyslipidemia, making them 2 to 
4 times more likely to develop cardiovascular disease than those without diabetes 
[90]
.  Even 
when effective glycemic control is achieved with antidiabetic treatment, dyslipidemia persists in 
many patients with diabetes, especially type 2 diabetes 
[86]
.  Antihyperlipidemic agents are used 
to control lipid levels.  Major antihyperlipidemic medications include HMG-CoA reductase 
inhibitors (statins), niacin, fibrates, and bile acid sequestrants 
[91]
.   Many statins, except 
pravastatin, are primarily metabolized by the cytochrome P450 system 
[87] [88]
, and may thus 
induce drug-drug interactions based on this mechanism.  
    There are concerns about multiple medication regimens for diabetes patients.  On average, a 
diabetes patient used 3.43 drug classes out of the top ten drug classes in this study.  Furthermore, 
significant variance exists in the number of drug classes used by each patient.  About 25% of the 
patients in this study used more than 5 drug classes, and 10% used more than 6 drug classes in 
2006.  The number of concurrent medications may be even larger than then number of drug 
classes, because many patients take combination therapy of antidiabetic agents.  Earlier studies 
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have shown that treatment with two or three drugs may not result in medication problems, but 
when the number of drugs exceeds four, patients are exposed to significant risks such as 
medication errors, medication noncompliance, and higher rates of hospitalization 
[92] [93]
.  
    On one hand, it is apparent that an increase in the number of co-medications tends to decrease 
the adherence of patients to their treatment regimens, and this may result in a more severe 
adverse reaction, higher rates of hospitalization and related healthcare costs.  On the other hand, 
drug-drug interactions are a concern when patients are taking multiple drugs.  Studies have found 
a positive association between the number of concurrent medications used and the potential for 
clinically relevant or potentially serious drug-drug interactions 
[94] [95]
.  As mentioned before, 
drugs that undergo metabolism by CYP 450 isoenzymes system, such as statins, TDZs are 
subject to induce drug-drug interactions if they are administered with some calcium channel 
blockers such as verapamil and diltiazem, which inhibit CYP 3A4 
[96]
.  For diabetes patients, the 
medications used to treat the complications may adversely affect the control of glucose.  For 
example, thiazide diuretics may be useful to treat mild to moderate hypertension but may induce 
glucose intolerance by diminishing insulin sensitivity 
[97]
.  Other drugs for hypertension, such as 
Beta-blockers, may inhibit beta-adrenergic stimulation of insulin secretion and mask some 
symptoms of hypoglycemia 
[76]
.  Especially, we found that 38% of our study population is of 65 
years age or older.  Older adults are more fragile to these risks of multi-medication regimens.  
Physiological changes associated with aging, such as decreased renal and hepatic function, 
decreased total body water and decreased lean body mass, requires special consideration in terms 
of the dosage and combination of the medications for elderly patients 
[20] [76]
.    
     The patterns of medication use among diabetes patients are potentially influenced by a web of 
factors.  Indeed, some of these factors are health status related, but demographic and socio-
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economic statuses are also important.  In this study, we explored the predictive effects of 
race/ethnicity and health insurance overage on the medication use patterns with consideration of 
other covariates mediating these effects.  After adjusting for other socio-demographic and 
geographic factors, including age, gender, education, marital status, family size, region, MSA, 
and poverty level, two predictors have demonstrated significant differences with regard to 
medication use among diabetes patients.  Generally, minorities have profoundly lower drug 
spending and use a lower number of drug classes than NonWhite -Hispanics. One possible 
explanation for this variation is cultural difference.  Ethnic culture affects our beliefs about 
health, illness, and medications, and it also influences how we comply with prescribed 
medications.  Studies indicated that Asian patients are more cautious about American 
medications and often initiate downward dosage adjustments to avoid potential adverse drug 
reactions 
[98]
.  Secondly, certain race or ethnic groups seem to be closely linked to disadvantaged 
socioeconomic position in terms of income, education and wealth 
[99]-[104]
.  The lower medication 
use and spending may somewhat reflect reduced access to health care, limited social support, or 
local discriminatory practices.  As for health insurance status, apart from the health conditions 
and aging factors, moral hazard could be an explanation for the disparities.  Patients with 
generous pharmaceutical benefits who have more access to medications may have incentive to 
use more drugs.  In this study, we used a hierarchy classification of the insurance coverage.  
Medicare enrollees, even if they have supplemental coverage from private insurance, are 
categorized into Medicare group.  Hence, patients with Medicare Part D have comparatively 
more generous benefits for prescribed medications.  These patients seem to have more total drug 
spending while less out-of-pocket payments than patients with other coverage, especially those 
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with private insurance only and without drug insurance.  Meanwhile, Medicare Part D enrollees 
are found to use more drug classes than private insurance patients and self-payers.   
    Compared to previous studies, the results of this study add greater depth to the picture of 
diabetes therapy complexity.  We identified ten therapeutic drug classes that are mostly used 
among diabetes patients.  Apart from three major components of diabetes therapies such as 
antidiabetic antihyperlipidemic, and antihypertensive agents, other agents, such as analgesics, 
PPIs, antidepressants, and diuretics are identified into the top ten drug classes that are used most 
often among diabetics, so that we obtained more detailed and comprehensive information about 
the medication use among diabetes patients.  Instead of using the visit as the unit of analysis, we 
used the person as the unit of analysis.  We calculated not only the medication use with regards 
to number of prescriptions and therapeutic drug classes in a year, but also the economic burden 
for individuals in terms of annual total drug spending and out-of-pocket payment.  We also 
provided evidence that the prescribed medication uses among diabetes patients vary across 
different races/ethnicities and different insurance coverage, after adjusting for other socio-
economic factors.  This heterogeneity in medication use and spending may reflect differences in 
the health care environments and indicates the importance of implementing individualized 
treatment strategies for diabetes patients. 
 
5.2 Limitations 
This is a cross-sectional study on a representative sample.  We described the relationship of 
the socio-economic variables with our study outcomes.  However, we were not able to establish 
causal relationships or obtain reliable perspectives on the outcomes from this study.  Secondly, 
we used a nationally representative survey dataset to gather demographic information and related 
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prescribed medicine records.  Some questions cannot be solved, given the limited information 
available in the database.  For example, we have one outlier in our sample with an extremely 
large amount of drug spending and usage, but we have no idea about the reason for these large 
values.  Furthermore, the sample sizes of certain minorities were too small to be stable.   
In addition, prescribed medication use is a crude measure in this study.  We can only obtain 
the total number of drug classes that are used in the year span.  However, we cannot distinguish 
between switches and addition of the drugs.  For instance, if a diabetes patient used drug class A 
and switched to class B later, we count the number of drug classes used as 2.  Meanwhile, when 
a diabetes patient used drug class A and added class B into his/her regimen later, we still count 2 
drug classes used by this patient.  Furthermore, we were unable to ascertain each patient’s health 
insurance status change.  We used the insurance coverage status on the last day of the year for 
each patient, which is imprecise.  For some people, insurance coverage changes over the year 
due to some reasons such as unemployment or retirement.  It is complex to grab and take into 
account all of these changes. 
Last but not least, we studied on the prescribed medication in this project with no regards to 
other medicines such as OTC and herbal drugs.  MEPS collects drug data prompted to look at 
prescribed medicines only.  However, this information is important as well.  Some analgesics are 
OTC drugs, and diabetes patients may not report this information in the survey.  Excluding these 
medications may provide conservative estimates as well as underestimates of cost and 
complexity of diabetes treatment.  More importantly, the effects of prescribed medication 
therapies may be affected because of drug-drug interactions or changes in the metabolism of the 
prescribed drugs 
[20] [105]
, which is a potential threat for drug safety. 
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5.3 Implications and future directions 
     The findings in this study are enlightening for patient care purposes.  The number of drug 
classes that are used by most of the diabetes patients are reaching or already exceeding the 
threshold for increased risks of falls, hypoglycemia, and other adverse drug events 
[10]
.  Hence, 
despite the fact that intensive treatment goals and multiple medications may bring benefits for 
diabetes patients, polypharmacy is likely to raise the concern of the risks of ADRs, nonadherence 
and drug-drug interactions for clinicians and patients with diabetes.  More efforts are needed on 
investigating how to optimize the clinical diabetes regimens in purpose to simultaneously 
increase the benefits and minimize the undesired consequences of polypharmacy.   
    Our results are also potentially useful for health policy planning.  Heterogeneous medication 
use and spending makes it prudent to focus health care quality improvement efforts on patients 
with poorer drug coverage or those who are at lower socio-economic positions.  For this purpose, 
more research is needed on a larger span of study periods, by which we may obtain the trends of 
the variance in medication use and spending across different socio-economic positions over time. 
 
5.4 Conclusions 
    In summary, diabetes patients used multiple therapeutic drug classes in 2006.  Antidiabetic 
and antihyperlipidemic agents were two classes that were mostly used by diabetes patients and 
had higher costs than other categories of medications.  We also found significant impacts of 
racial/ethnic and insurance coverage status differences on medication utilization and expenditure, 
after adjusting for other pertinent covariates among individuals with diabetes mellitus.  
Knowledge about the complexity of diabetes therapy and the characterization of the socio-
economic variations will enable quality improvement of diabetes care. 
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Table A-1  Weighted multivariate regression in total drug spending per person in 2006 
Independent Variables Coef. (95% CI) P>|z| 
Age   
65-85 Referent 
18-44 -0.21 (-0.44, 0.02) 0.074 
45-64 0.17 (-0.015, 0.36) 0.071 
Gender   
Female Referent 
Male -0.058 (-0.16, 0.043) 0.258 
Race   
White nonhispanic Referent 
White hispanic -0.14 (-0.31, 0.021) 0.086 
Black -0.13 (-0.28, 0.013) 0.073 
Asian -0.42 (-0.69, -0.14) 0.003* 
American Indian or Alaska Native -0.39 (-0.74, -0.032) 0.033* 
Native Hawaiian or Pacific Islander -0.65 (-1.23, -0.069) 0.028* 
Multiple race 0.16 (-0.27, 0.59) 0.47 
Region   
South Referent 
Northeast 0.11 (-0.03, 0.25) 0.125 
West  -0.053 (-0.20, 0.09) 0.47 
Midwest -0.11 (-0.24, 0.021) 0.100 
MSA status  
MSA Referent 
NonMSA 0.13 (0.0004, 0.24) 0.049* 
Education Year  
≤ 11 Referent 
≥ 12 0.054 (-0.065, 0.173) 0.376 
Marital status   
Married Referent 
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Marital status                  Widowed -0.073 (-0.25, 0.11) 0.423 
Divorced -0.063 (-0.23, 0.10) 0.447 
Separated -0.46 (-0.81, -0.11) 0.009* 
Never married 0.065 (-0.15, 0.28) 0.549 
Family size   
=1 Referent 
> 1 0.10(-0.051, 0.25) 0.193 
Poverty level   
Middle income Referent 
Poor -0.034 (-0.21, 0.14) 0.702 
Near poor -0.072 (-0.29, 0.14) 0.514 
Low income -0.09a (-0.25, 0.066) 0.255 
High income 0.050 (-0.075, 0.17) 0.435 
Health Insurance Coverage   
Medicare part D Referent 
Medicare nonpart D -0.17 (-0.31, -0.02) 0.024* 
Medicaid 0.24 (-0.024, 0.51) 0.075 
Private insurance coverage -0.48 (-0.68, -0.28) 0.000* 
Self-pay -0.74 (-0.97, -0.50) 0.000* 
General Health Perception  
Fair  Referent 
Excellent -0.40 (-0.64, -0.17) 0.001* 
Very good -0.19 (-0.33, -0.038) 0.014* 
Good -0.20 (-0.33, -0.080) 0.001* 
Poor 0.17 (-0.00063, 0.34) 0.051 
Comorbidities   
Asthma 0.35 (0.20, 0.50) 0.000* 
High cholesterol 0.29 (0.19, 0.39) 0.000* 
Angina 0.012 (-0.20, 0.22) 0.911 
Coronary heart disease 0.25 (0.077, 0.43) 0.005* 
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Comorbidities              Heart attack -0.11 (-0.30, 0.071) 0.229 
Other heart disease 0.16 (0.017, 0.30) 0.028* 
Stroke 0.024 (-0.16, 0.21) 0.797 
Arthritis 0.12 (0.016, 0.23) 0.025* 
 Emphysema 0.17 (-0.087, 0.42) 0.198 
High blood pressure 0.34 (0.23, 0.45) 0.000* 
This model included race/ethnicity, health insurance coverage status as main predictors.  
The remaining variables were included as covariates (age, gender, education, region, 
MSA status, marital status, family size, poverty level, general health perception, and 
comorbidities).   
“Referent” refers to the comparison group.   
“*” Statistically significant at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
Table A-2  Weighted multivariate regression in out-of-pocket payment per person in 2006 
Independent Variables Coef. (95% CI) P>|z| 
Age   
65-85 Referent 
18-44 -0.31 (-0.56, 0.058) 0.017* 
45-64 0.028 (-0.17, 0.23) 0.788 
Gender   
Female Referent 
Male -0.14 (-0.25, -0.026) 0.016* 
Race   
White nonhispanic Referent 
White hispanic -0.094 (-0.28, 0.09) 0.326 
Black -0.078 (-0.24, 0.086) 0.353 
Asian -0.61 (-0.92, -0.29) 0.000* 
American Indian or Alaska Native -0.51 (-0.91, -0.11) .0013* 
Native Hawaiian or Pacific Islander -0.97 (-1.62, -0.32) 0.004* 
Multiple race -0.49 (-0.95, -0.026) 0.038* 
Region   
South Referent 
Northeast -0.0016 (-0.16, 0.15) 0.984 
West -0.0017 (-0.16, 0.16) 0.984 
Midwest -0.15 (-0.29, -0.0058) 0.041* 
MSA status   
MSA Referent 
NonMSA 0.11 (-0.026, 0.25) 0.111 
Education Year   
≤ 11 Referent 
≥ 12 0.15 (0.014, 0.28) 0.030* 
Marital status   
Married Referent 
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Widowed 0.527 (-0.14, 0.26) 0.527 
Divorced -0.23 (-0.42, -0.047) 0.014* 
Separated -0.35 (-0.74, 0.037) 0.076 
Never married -0.056 (-0.29, 0.18) 0.645 
Family size   
=1 Referent 
> 1 0.010 (-0.16, 0.18) 0.910 
Poverty level  
Middle income Referent 
poor -0.14 (-0.34, 0.054) 0.156 
Near poor 0.031 (-0.21, 0.27) 0.802 
Low income 0.013 (-0.16, 0.19) 0.885 
High income -0.029 (-0.17, 0.11) 0.689 
Health Insurance Coverage   
Medicare part D Referent 
Medicare nonpart D 0.11 (-0.050, 0.27) 0.177 
Medicaid -0.27 (-0.60, 0.038) 0.087 
Private insurance coverage -0.021 (-0.24, 0.20) 0.846 
Self-pay 0.41 (0.14, 0.67) 0.003* 
General Health Perception  
Fair  Referent 
Excellent -0.34 (-0.60, -0.071) 0.013* 
Very good -0.13 (-0.30, 0.039) 0.134 
Good -0.065 (-0.21, 0.08) 0.362 
Poor 0.29 (0.10, 0.49) 0.003* 
Comorbidities   
Asthma 0.32 (0.15, 0.49) 0.000* 
High cholesterol 0.24 (0.13, 0.36) 0.000* 
Angina 0.14 (-0.096, 0.37) 0.250 
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Coronary heart disease 0.14 (-0.057, 0.34) 0.161 
Heart attack 0.029 (-0.18, 0.24) 0.784 
Other heart disease 0.16 (0.0041, 0.32) 0.044* 
Stroke 0.013 (-0.17, 0.22) 0.901 
Arthritis 0.043 (-0.081, 0.17) 0.497 
 Emphysema 0.12 (-0.17, 0.40) 0.419 
High blood pressure 0.30 (0.18, 0.43) 0.000* 
This model included race/ethnicity, health insurance coverage status as main predictors.  
The remaining variables were included as covariates (age, gender, education, region, MSA 
status, marital status, family size, poverty level, general health perception, and 
comorbidities).   
“Referent” refers to the comparison group.   
“*” Statistically significant at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
Table A-3  Weighted multivariate regression in number of therapeutic classes used per 
person in 2006 
Independent Variables Coef. (95% CI) P>|z| 
Age   
65-85 Referent 
18-44 -0.11 (-0.20, 0.0092) 0.032* 
45-64 0.091 (0.012, 0.17) 0.024* 
Gender   
Female Referent 
Male -0.053 (-0.096, -0.0098) 0.016* 
Race   
White nonhispanic Referent 
White hispanic -0.092 (-0.16, -0.024) 0.008* 
Black -0.030 (-0.091, 0.031) 0.336 
Asian -0.09 (-0.21, 0.028) 0.133 
American Indian or Alaska Native -0.15 (-0.30, -0.0015) 0.048* 
Native Hawaiian or Pacific Islander -0.24 (-0.48, -0.0046) 0.05* 
Multiple race -0.085 (-0.26, 0.089) 0.338 
Region   
South Referent 
Northeast -0.0164 (-0.074, 0.041) 0.574 
West  0.020 (-0.038, 0.078) 0.508 
Midwest 0.011 (-0.044, 0.066) 0.692 
MSA status  
MSA Referent 
NonMSA 0.020 (-0.031, 0.71) 0.442 
Education Year  
≤ 11 Referent 
≥ 12 0.032 (-0.018, 0.082) 0.204 
Marital status   
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Married Referent 
Widowed -0.12 (-0.19, -0.040) 0.003* 
Divorced -0.087 (-0.15, -0.019) 0.012* 
Separated -0.069 (-0.22, 0.079) 0.360 
Never married 0.020 (-0.068, 0.11) 0.659 
Family size   
=1 Referent 
> 1 0.093 (0.029, 0.16) 0.005* 
Poverty level  
Middle income Referent 
Poor 0.045 (-0.028, 0.12) 0.224 
Near poor 0.061 (-0.030, 0.15) 0.187 
Low income 0.014 (-0.051, 0.079) 0.668 
High income 0.011 (-0.041, 0.064) 0.667 
Health Insurance Coverage   
Medicare part D Referent 
Medicare nonpart D -0.011 (-0.071, 0.050) 0.724 
Medicaid -0.039 (-0.15, 0.072) 0.488 
Private insurance coverage -0.21 (-0.29, -0.12) 0.000* 
Self-pay -0.33 (-0.43, -0.23) 0.000* 
General Health Perception  
Fair  Referent 
Excellent -0.092 (-0.19, 0.0064) 0.067 
Very good -0.08 (-0.14, -0.020) 0.009* 
Good -0.037 (-0.089, 0.015) 0.164 
Poor 0.015 (-0.057, 0.087) 0.690 
Comorbidities   
Asthma 0.10 (0.039, 0.16) 0.002* 
High cholesterol 0.32 (0.28, 0.36) 0.000* 
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Comorbidities                      Angina 0.11 (0.027, 0.20) 0.010* 
Coronary heart disease 0.22 (0.14, 0.30) 0.000* 
Heart attack 0.027 (-0.05, 0.11) 0.505 
Other heart disease 0.14 (0.085, 0.20) 0.000* 
Stroke -0.0091 (-0.086, 0.068) 0.817 
Arthritis 0.11 (0.064, 0.15) 0.000* 
 Emphysema -0.047 (-0.15, 0.059) 0.384 
High blood pressure 0.46 (0.41, 0.51) 0.000* 
This model included race/ethnicity, health insurance coverage status as main predictors.  The 
remaining variables were included as covariates (age, gender, education, region, MSA status, 
marital status, family size, poverty level, general health perception, and comorbidities).   
“Referent” refers to the comparison group.   
“*” Statistically significant at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
 
Vita 
 
 
Jing Tao was born in Shanghai, China on April 29th, 1981. She is a Chinese resident currently 
living in Richmond, Virginia.  She obtained her Bachelor of Science Degree in Pharmacy in 
2003 from Fudan University in Shanghai, China.  From Aug 2003 till Jun 2008, she worked as a 
pharmacist in Shanghai Ruijin Hospital, which is one of the top hospitals in China.  Her major 
duties included statistical analyses and reports for Shanghai Antimicrobiotic Drugs Use 
Monitoring Network, ADR case collection and reports, and individualized therapy design of 
immunosuppresants for patients in Renal Transplantation Center in Ruijin Hospital.  In August 
2009, she started her graduate study in Pharmacotherapy and Outcome Science at Virginia 
Commonwealth University, School of Pharmacy, where she worked as a teaching assistant.  In 
the two-year program training, she accomplished three projects with her advisor.  Currently she 
is pursuing a Master’s Degree with the thesis research related with database analyses on diabetes 
therapy. 
 
 
 
 
 
84 
 
EDUCATION 
Aug, 2009 - Aug, 2011     MS in Pharmacotherapy and Outcome Sciences, Department of 
Pharmacotherapy and Outcome Science, Virginia Commonwealth 
University. 
Sep, 1999 - Jul, 2003         B.Sc.Pharm, School of Pharmacy, Fudan University. 
 
PROFESSIONAL EXPERIENCE 
Aug, 2009 – Aug 2011 Teaching assistant at School of Pharmacy, Virginia Commonwealth 
University 
Jun, 2005 – Jun, 2008 Clinical pharmacist at Clinical Pharmacology Laboratory, Shanghai 
Ruijin Hospital 
Aug, 2003 – May, 2005 Rotation pharmacist in Shanghai Ruijin Hospital 
 
 
CONFERENCE PRESENTATIONS 
Tao J, Zhang JX.    The complexity of drug therapy and socio-economic variants in patients with 
diabetes. International Society for Pharmacoecnomics and Outcome Research (ISPOR) 16th 
Annual International Meeting, Baltimore, MD, USA, May 2011 (Poster presentation) 
 
Tao J, Zhang JX.    Is good insurance bad for antibiotic prescribing: the case of acute respiratory 
tract infections in adult primary care. AcademyHealth's Annual Research Meeting (ARM), 
Boston, MA, USA, June 2010 (Poster presentation) 
 
85 
 
Tao J, Zhang JX. Antibiotic prescribing for acute respiratory tract infections in adult primary 
care: Is good insurance bad for antibiotic prescribing?  International Society for 
Pharmacoecnomics and Outcome Research (ISPOR) 15th Annual International Meeting, Atlanta, 
GA, USA, May 2010 (Poster presentation, Finalist Award) 
 
Zhang JX, Tao J. Market concentration and its cross-linkage with consumption of ACE 
Inhibitors and ARBs. International Society for Pharmacoecnomics and Outcome Research 
(ISPOR) 12th Annual European Congress, Paris, France, October 2009 (Podium presentation) 
